Edition:
United States

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

38.34USD
22 Sep 2017
Change (% chg)

$0.67 (+1.78%)
Prev Close
$37.67
Open
$37.65
Day's High
$38.47
Day's Low
$37.65
Volume
54,046
Avg. Vol
92,259
52-wk High
$38.72
52-wk Low
$24.48

Chart for

About

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $1,580.05
Shares Outstanding(Mil.): 41.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

BRIEF-Emergent BioSolutions awarded $63 mln BARDA contract to develop treatment for cyanide exposure

* Emergent BioSolutions - awarded contract valued at about $63 mln by Biomedical Advanced Research And Development Authority

Sep 18 2017

BRIEF-Emergent Biosolutions Q2 earnings per share $0.11

* Emergent Biosolutions reports second quarter and six months 2017 financial results; reaffirms calendar year 2017 guidance

Aug 03 2017

BRIEF-Emergent Biosolutions awarded $23 mln to develop novel multi-drug auto-injector for U.S. Department Of Defense

* Emergent Biosolutions awarded $23 million to develop novel multi-drug auto-injector for U.S. Department of defense Source text for Eikon: Further company coverage:

Jul 31 2017

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

* Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

Jul 26 2017

BRIEF-Emergent Biosolutions to acquire Raxibacumab from GSK

* Emergent Biosolutions to acquire Raxibacumab, an FDA-approved Anthrax monoclonal antibody, from GSK

Jul 19 2017

BRIEF-Emergent Biosolutions updates terms of termination of agreement related to acquisition of Sanofi's acam2000 business

* Emergent Biosolutions updates on terms of any termination of agreement related to acquisition of acam2000 business from Sanofi

Jul 14 2017

BRIEF-Emergent BioSolutions to acquire ACAM2000 business from Sanofi

* Emergent biosolutions to acquire acam2000® business from sanofi

Jul 14 2017

BRIEF-Emergent Biosolutions reports Q1 revenue $116.9 million

* Emergent Biosolutions reports first quarter 2017 financial results; reaffirms 2017 guidance

May 04 2017

BRIEF-Emergent Biosolutions signs $53 mln modification to Barda contract for manufacture of botulism antitoxin

* Emergent Biosolutions signs $53 million modification to Barda contract for the manufacture of botulism antitoxin

Mar 31 2017

Competitors

Earnings vs. Estimates